Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Deborah Collyar: What's In It for Patients?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Oct
28
Today In Oncology
TIL Therapy Plus Pembrolizumab for Advanced Melanoma
Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction
Sacituzumab Tirumotecan Extends PFS OS in Advanced Recurrent Endometrial Cancer
Expert Histopathology and Molecular Testing Improve Diagnosis of Ambiguous Cutaneous Melanocytic Tumors
Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo